Author Archives: Bruno Quinney

#Sickle cells #Sub-Saharan Africa

African initiative to support sickle cell disease care 

A regional initiative has been launched across Africa to help countries strengthen sickle cell disease care.  The Imara Sickle Cell Framework, led by African health leaders and partners, is designed to translate policy priorities into practical, coordinated care delivery within national health systems.  Initial implementation… Read More

#News

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 23 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More

#Podcasts

Corporate collaboration
#Drug discovery #Merck

Protillion and Merck unveil drug discovery collaboration  

Protillion Biosciences has signed a drug discovery collaboration with Merck to “identify novel therapeutic candidates.”  The agreement combines Protillion’s proprietary platform, Prot-MaP, with Merck’s expertise in the discovery of novel therapeutic candidates.  The Prot-MaP technology is a megascale data generation platform, which Protillion says is purpose-built to deliver massive, just-in-time training sets to protein design… Read More

#News

#AI #ASCO #Cancer Research UK #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

This week in Drug Discovery (15 June – 19 June) 

News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW.  This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research.  The top stories:     … Read More

#News

#Biotech #Broken String Biosciences #Gene editing

Broken String Biosciences appoints Bruce Eaton to board 

Broken String Biosciences has appointed Bruce Eaton as Chairman of the Board.  The appointment from the biotechnology company allows it to drive the global commercialisation of its INDUCE-seq platform, which it says can provide rapid, unbiased, genome-wide measurement of on- and off-target DNA breaks directly in customers’ own… Read More

#News

Leukaemia
#Acute Myeloid Leukaemia #Clinical trial

CERo reports positive data from AML Phase I trial 

CERo Therapeutics has reported encouraging data from a Phase I trial evaluating a treatment for haematologic malignancies in acute myeloid leukaemia (AML).  In the CERTAIN-T trial, a patient with multiple refractory AML – who had not previously achieved disease control sufficient to enable allogeneic stem cell transplantation – showed 7% bone… Read More

#News

Fibrous dysplasia disease
#Fibrotic disease #Inflammatory diseases #Macrophages #Resolution Therapeutics

Resolution extends pipeline with in vivo RMT 

Resolution Therapeutics has extended its inflammatory and fibrotic disease pipeline with its in vivo regenerative macrophage therapy (RMT).  The announcement comes with Resolution executing Material Transfer Agreements with independent, best-in-class lipid nanoparticle (LNP) technology providers. Under the agreements, Resolution will conduct systematic assessments of LNP formulations for the engineering… Read More

#News

Ovarian cancer cells
#Clinical trial #Immunology / Virology & Vaccines #Mayo Clinic #Ovarian cancer

Ovarian cancer vaccine with 40% survival rate to be advanced 

A new agreement is set to advance a vaccine for ovarian cancer which has shown 40% cancer-free survival rates.  Biotechnology company CellxLife has entered an agreement with Mayo Clinic for the dendritic cell vaccine, which reported the 40% 10-year cancer-free survival rate in a Phase I Mayo Clinic study compared to the… Read More

#Business & Investment #Cancer Research #News

#AdipoPharma #GLP-1 #Obesity #Weight loss

Could a new weight loss approach have longer term benefits than GLP-1s?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Vincent Marion, Scientific Founder and President of AdipoPharma. AdipoPharma is a biotech leveraging research on insulin resistance and adipose tissue biology, developing a new treatment for metabolic diseases. Vincent… Read More

#Featured Podcasts #Podcasts

#GLP-1 #MHRA #Obesity #UK #Weight loss

Wegovy pill could help patients lose 17% body weight 

The new Wegovy pill could help patients lose 17% of their body weight, clinical trial results show.  The tablet version of Wegovy, approved in the UK by MHRA, is the first GLP-1 weight-loss pill licensed for weight management in the UK and is expected to become available… Read More

#News

World Parkinson's Day
#AskBio #Blood brain barrier #FDA #Gene therapy #Parkinson's #Regulatory

How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease

Bruno Quinney speaks to Adrian Kells, Senior Vice President and Integrated Product Team Lead PD at AskBio, about the company’s gene therapy programme and pioneering treatment for Parkinson’s. The drug discovery landscape for Parkinson’s disease is becoming one of the most exciting frontiers in the industry. It is unsurprising to… Read More

#Exclusive Content

Myeloma
#Clinical trial #Combination therapy #Myeloma

Therapy enables 89% survival rate in myeloma patients 

A combination treatment has demonstrated strong survival rates in patients with earlier-line relapsed or refractory multiple myeloma.  Talvey (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide showed a progression-free survival rate of up to 81.3% versus standard of care (51.2%) and an overall survival… Read More

#Cancer Research #News

Blood tests in laboratory
#Clinical trial #Ulcerative colitis (UC)

Ulcerative colitis treatment shows best-in-class potential 

An anti-TL1A has demonstrated its potential to be a best-in-class treatment for ulcerative colitis.  Biotechnology company Spyre Therapeutics reported results from the Phase II SKYLINE trial evaluating SPY002, an extended half-life investigational antibody targeting TL1A. TL1A is an upstream cytokine implicated in chronic inflammation and fibrosis in inflammatory… Read More

#News

Pills
#MHRA #Obesity #UK #Weight loss

UK patients to benefit from approval of weight loss tablet  

UK patients will soon have access to a weight loss tablet following a landmark approval by the Medicines and Healthcare products Regulatory Agency (MHRA).  The body has approved oral Wegovy, which could be rolled out to as many as 100,000 patients living in the UK.  Research from healthcare company Simple… Read More

#News #Regulatory

#Cancer research #Clinical trial #Drug discovery #Francis Crick Institute #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

DDW Highlights: 16 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed anti-IL-1β drugs could prevent lung cancer. Elsewhere, the… Read More

#Podcasts